Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

GNTA

Genenta Science SpA ADR

Jun 14 • 04:00PM ET

3.24

Dollar change +0.07
Percentage change 2.12	%

Healthcare • Biotechnology • Italy • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.69	Insider Own	-	Shs Outstand	18.22M	Perf Week	-1.90%
Market Cap	58.98M	Forward P/E	-	EPS next Y	-1.08	Insider Trans	-	Shs Float	-	Perf Month	4.43%
Income	-12.59M	PEG	-	EPS next Q	-	Inst Own	5.35%	Short Float	-	Perf Quarter	-18.50%
Sales	0.00M	P/S	-	EPS this Y	-66.06%	Inst Trans	-	Short Ratio	0.57	Perf Half Y	-35.57%
Book/sh	1.24	P/B	2.61	EPS next Y	-17.86%	ROA	-	Short Interest	0.00M	Perf Year	-45.77%
Cash/sh	1.14	P/C	2.84	EPS next 5Y	-	ROE	-	52W Range	2.20 - 6.39	Perf YTD	-34.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-24.90%	ROI	-55.78%	52W High	-49.34%	Beta	0.77
Dividend TTM	-	Quick Ratio	12.25	Sales past 5Y	0.00%	Gross Margin	-	52W Low	47.15%	ATR (14)	0.21
Dividend Ex-Date	-	Current Ratio	12.25	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	48.63	Volatility	1.50% 4.50%
Employees	14	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	25.22
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	0.08	Prev Close	3.17
Sales Surprise	-	EPS Surprise	28.25%	Sales Q/Q	-	Earnings	Feb 28	Avg Volume	5.96K	Price	3.24
SMA20	-0.51%	SMA50	-2.20%	SMA200	-28.32%	Trades		Volume	453	Change	2.12%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-29-23	Resumed	ROTH MKM	Buy	$15
Jul-25-22	Initiated	H.C. Wainwright	Buy	$25
Jan-13-22	Initiated	Maxim Group	Buy	$21

May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace)
May-06-24 06:25AM	Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider (GlobeNewswire)
Feb-08-24 05:00AM	Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors (GlobeNewswire)
Sep-06-23 07:00AM	Genenta to Present at Upcoming Scientific and Investor Conferences (GlobeNewswire)
Jul-28-23 03:00AM	Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments (GlobeNewswire) -6.29%
09:57AM	Loading…
Jul-08-23 09:57AM	Here's Why We're Not Too Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn Situation (Simply Wall St.)
Jun-29-23 07:00AM	The European Commission Grants Orphan Drug Designation to Temferon for Treatment of Glioma (GlobeNewswire)
May-17-23 06:34AM	Insiders own 30% of Genenta Science S.p.A. (NASDAQ:GNTA) shares but individual investors control 59% of the company (Simply Wall St.)
May-16-23 07:00AM	Genenta to Provide Update on Lead Product Temferon (GlobeNewswire) +9.80%
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-02-23 03:30PM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
Apr-26-23 07:00AM	Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing (GlobeNewswire)
Apr-03-23 07:00AM	Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications (GlobeNewswire)
Mar-02-23 06:45AM	FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme (GlobeNewswire)
Feb-07-23 07:00AM	Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement (GlobeNewswire)
07:45AM	Loading…
Jan-29-23 07:45AM	We Think Genenta Science (NASDAQ:GNTA) Can Easily Afford To Drive Business Growth (Simply Wall St.)
Dec-08-22 05:16AM	Genenta Science S.p.A. (NASDAQ:GNTA) most popular amongst individual investors who own 60%, insiders hold 29% (Simply Wall St.)
Nov-07-22 08:05AM	Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon Treatment in Glioblastoma Patients (GlobeNewswire) +8.62%
Oct-24-22 07:30AM	Genenta Provides First Half 2022 Business Update and Financial Results (GlobeNewswire)
Oct-17-22 10:27AM	10 Best Italian Stocks To Buy Now (Insider Monkey)
Oct-05-22 08:05AM	Genenta to Present at Upcoming Scientific and Investor Conferences (GlobeNewswire)
Sep-07-22 07:00AM	Genenta to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-22-22 07:06AM	We're Not Very Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn Rate (Simply Wall St.) -7.38%
Jul-25-22 06:00AM	AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative (GlobeNewswire)
May-27-22 09:40AM	What Kind Of Investors Own Most Of Genenta Science S.p.A. (NASDAQ:GNTA)? (Simply Wall St.) +9.56%
May-13-22 07:30AM	Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA (GlobeNewswire)
May-09-22 07:30AM	Genenta Appoints Industry Veteran Tim Obara as Head of Business Development (GlobeNewswire)
May-04-22 04:30PM	Genenta Files Annual Report on Form 20-F for Fiscal Year 2021 (GlobeNewswire)
07:30AM	Genenta Progresses to Higher Dosing Cohort in Temferon Phase 1/2a Clinical Trial in Glioblastoma Multiforme (GlobeNewswire)
May-02-22 04:30PM	Genenta ASGCT Clinical Data Highlights Temferon Biological Effects in Glioblastoma (GlobeNewswire) +5.52%
07:30AM	Loading…
Apr-27-22 07:30AM	Genenta Announces Nomination of Mark A. Sirgo as Chair (GlobeNewswire)
Apr-20-22 07:30AM	Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors (GlobeNewswire)
Mar-15-22 06:34AM	Is Genenta Science (NASDAQ:GNTA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) +5.89%
Mar-09-22 07:46AM	Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon in Unmethylated Glioblastoma Multiforme (GlobeNewswire)
Feb-24-22 07:30AM	Genenta to Participate at Upcoming Investor Conferences (GlobeNewswire) -11.37%
Dec-17-21 04:15PM	Genenta Closes Its Upsized Initial Public Offering of American Depository Shares (GlobeNewswire)
Dec-14-21 10:36PM	Genenta Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GNTA

Genenta Science SpA ADR

Upgrade your FINVIZ experience